A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 8, 2015, Pages 734-741

  Pacifico, L ^a   Bonci, E ^a   Di Martino, M ^a   Versacci, P ^a   Andreoli, G ^a   Silvestri, L M ^a   Chiesa, C ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Cardiac function; Children; Docosahexaenoic acid; Epicardial adipose tissue; Liver fat; NAFLD; Visceral adipose tissue

Indexed keywords

ALANINE AMINOTRANSFERASE; DOCOSAHEXAENOIC ACID; PLACEBO; TRIACYLGLYCEROL; INSULIN; UNSATURATED FATTY ACID;

ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOPSY; BODY COMPOSITION; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER FAT; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADIPOSE TISSUE; ADOLESCENT; BLOOD; BODY MASS; DIET RESTRICTION; DIET THERAPY; DRUG EFFECTS; HUMAN; LIVER; OBESITY; PATHOLOGY; PERICARDIUM; RISK FACTOR;

ADIPOSE TISSUE; ADOLESCENT; ALANINE TRANSAMINASE; BIOPSY; BODY MASS INDEX; CHILD; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; LIVER; MAGNETIC RESONANCE IMAGING; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PERICARDIUM; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT;

EID: 84937513927     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2015.04.003     Document Type: Article

References (34)

1. Mencin A.A., Lavine J.E. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am 2011, 58:1375-1392.
2. D'Adamo E., Cali A.M., Weiss R., Santoro N., Pierpont B., Northrup V., et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 2010, 33:1817-1822.
3. Pacifico L., Chiesa C., Anania C., De Merulis A., Osborn J.F., Romaggioli S., et al. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 2014, 20:9055-9071.
4. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
5. Schwimmer J.B., Pardee P.E., Lavine J.E., Blumkin A.K., Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008, 118:277-283.
6. Pacifico L., Anania C., Martino F., Cantisani V., Pascone R., Marcantonio A., et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1643-1651.
7. Perseghin G., Lattuada G., De Cobelli F., Esposito A., Belloni E., Ntali G., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008, 47:51-58.
8. Goland S., Shimoni S., Zornitzki T., Knobler H., Azoulai O., Lutaty G., et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006, 40:949-955.
9. Pacifico L., Di Martino M., De Merulis A., Bezzi M., Osborn J.F., Catalano C., et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2014, 59:461-470.
10. Lorente-Cebrián S., Costa A.G., Navas-Carretero S., Zabala M., Martínez J.A., Moreno-Aliaga M.J. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem 2013, 69:633-651.
11. Pacifico L., Giansanti S., Gallozzi A., Chiesa C. Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome. Mini Rev Med Chem 2014, 14:791-804.
12. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O'Connor H.T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012, 56:944-951.
13. Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Hodson L., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the *WELCOME study. Hepatology 2014, 60:1211-1221. on behalf of the WELCOME Study Investigators.
14. Nobili V., Bedogni G., Alisi A., Pietrobattista A., Risé P., Galli C., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomized controlled clinical trial. Arch Dis Child 2011, 96:350-353.
15. Nobili V., Alisi A., Della Corte C., Risé P., Galli C., Agostoni C., et al. Docosahexaenoic acid for the treatment of fatty liver: randomized controlled trial in children. Nutr Metab Cardiovasc Dis 2013, 23:1066-1070.
16. Cottin S.C., Sanders T.A., Hall W.L. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011, 70:215-231.
17. Cole T.J., Bellizzi M.C., Flegal K.M., Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000, 320:1240-1243.
18. Pacifico L., Arca M., Anania C., Cantisani V., Di Martino M., Chiesa C. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2013, 23:1010-1016.
19. Pacifico L., Di Martino M., Catalano C., Panebianco V., Bezzi M., Anania C., et al. T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. World J Gastroenterol 2011, 17:3012-3019.
20. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
21. Brunt E.M., Kleiner D.E., Wilson L.A., Belt P., Neuschwander-Tetri B.A. NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53:810-820.
22. Marangoni F., Colombo C., Galli C. A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans: applicability to nutritional and epidemiological studies. Anal Biochem 2004, 326:267-272.
23. Nobili V., Carpino G., Alisi A., De Vito R., Franchitto A., Alpini G., et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One 2014, 9:e88005.
24. Mishra P., Younossi Z.M. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007, 102:2716-2717.
25. Le T.A., Chen J., Changchien C., Peterson M.R., Kono Y., Patton H., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012, 56:922-932. for San Diego Integrated NAFLD Research Consortium (SINC).
26. Daniels S.R., Khoury P.R., Morrison J.A. Utility of different measures of body fat distribution in children and adolescents. Am J Epidemiol 2000, 152:1179-1184.
27. Nielsen S., Guo Z., Johnson C.M., Hensrud D.D., Jensen M.D. Splanchnic lipolysis in human obesity. J Clin Invest 2004, 113:1582-1588.
28. Iacobellis G., Bianco A.C. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011, 22:450-457.
29. Iacobellis G., Barbarini G., Letizia C., Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring) 2014, 22:332-336.
30. Kankaanpää M., Lehto H.R., Pärkkä J.P., Komu M., Viljanen A., Ferrannini E., et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006, 91:4689-4695.
31. Duda M.K., O'Shea K.M., Tintinu A., Xu W., Khairallah R.J., Barrows B.R., et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload induced cardiac dysfunction. Cardiovasc Res 2008, 81:319-327.
32. Fang Y., Favre J., Vercauteren M., Laillet B., Remy-Jouet I., Skiba M., et al. Reduced cardiac remodelling and prevention of glutathione deficiency after omega-3 supplementation in chronic heart failure. Fundam Clin Pharmacol 2011, 25:323-332.
33. Halade GV, Williams PJ, Lindsey ML, Fernandes G. Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacol Res 2011; 63: 300-7.
34. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.